Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bullous pemphigoid: from bench to bedside.

Scott R A Walsh1, David Hogg, P Régine Mydlarski

  • 1Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.

Drugs
|May 17, 2005
PubMed
Summary

Bullous pemphigoid (BP) is an autoimmune blistering disease primarily affecting the elderly. Current research suggests topical corticosteroids as a first-line treatment, with tetracyclines and other agents for specific cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-simulated clinical consultations: Assessing the potential of ChatGPT to support medical training.

Archives of disease in childhood·2026
Same author

Response to Reader Comment on: Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.

Journal of cutaneous medicine and surgery·2025
Same author

Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.

Journal of cutaneous medicine and surgery·2025
Same author

Dupilumab as a treatment for bullous pemphigoid in a liver transplant recipient: A case report.

SAGE open medical case reports·2025
Same author

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.

JTO clinical and research reports·2025
Same author

National Trends in Healthcare Expenditures for the Management of Skin Cancer in the United States.

Journal of cutaneous medicine and surgery·2024

Area of Science:

  • Dermatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Bullous pemphigoid (BP) is a chronic autoimmune blistering skin disease.
  • It predominantly affects the elderly population and presents with various clinical forms.
  • Autoantibodies target hemidesmosomal antigens (BP230, BP180) in the skin basement membrane.

Purpose of the Study:

  • To summarize the understanding of bullous pemphigoid pathogenesis and treatment.
  • To highlight current therapeutic recommendations for BP management.

Main Methods:

  • Review of clinical variants and immunopathogenesis of BP.
  • Analysis of recent clinical trial data on therapeutic interventions.
  • Detection methods for autoantibodies and complement in BP.

Main Results:

  • BP involves autoantibodies targeting BP230/BP180, leading to complement activation and blistering.
  • Potent topical corticosteroids are recommended as first-line therapy.
  • Tetracyclines may benefit mild BP; oral corticosteroids and steroid-sparing agents are used for severe or resistant cases.

Conclusions:

  • Effective management of bullous pemphigoid involves targeted therapies based on disease severity.
  • Topical corticosteroids are the primary treatment, with adjunctive therapies for specific patient subsets.

Related Experiment Videos